Antibody binding to FcRn for treating autoimmune diseases
TW201714621A
Antibody binding to fcrn for treating autoimmune diseases
KR20160141044A
Extended Release Formulation for Oral Administration of Sildenafil
KR20160141045A
Pharmaceutical composition containing of Bosentan
WO2015167293A1
Antibody binding to fcrn for treating autoimmune diseases
KR20150060099A
Pharmaceutical composition comprising n1-cyclic amine-n5-substituted bigunide derivatives as an ingredient for preventing or treating aging-induced cognitive decline
KR20150055986A
Extended Release Formulation for Oral Administration of Bosentan
KR20150052419A
Biguanide compounds and use thereof
KR20150051016A
Guanidine compounds and use thereof
US2014235558A1
Pharmaceutical composition having activity of anticancer
KR20140147606A
FcRn specific human antibody and composition for treatment of autoimmune diseases
KR20140137681A
Pharmaceutical composition comprising n1-cyclic amine-n5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis
CN104487057A
Bosentan controlled release oral preparation
CN104394881A
New uses of modified human tumor necrosis factor receptor-1 polypeptide
KR20140101073A
N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR20140101074A
N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR20140096671A
Pharmaceutical composition comprising n1-cyclic amine-n5-substituted biguanide derivatives as an ingredient for preventing or treating jet-lag syndrom
US2013071471A1
Pharmaceutical composition for treating atopic dermatitis
WO2013022280A2
N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR20130018622A
N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same